Cell-CT, the proprietary 3D imaging platform created by VisionGate, can detect lung cancer in sputum samples with high sensitivity and specificity, according to data presented at the 15th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.
The pilot study analyzed sputum samples from healthy controls, as well as with confirmed lung cancer. Using patient sputum collected from a spontaneous cough, the Cell-CT was able to accurately detect the presence or absence of lung cancer cells with a sensitivity of more than 95% and specificity of 99.8%.
According to VisionGate, the potential ability of its Cell-CT platform to non-invasively and cost-effectively confirm or refute positive results from x-ray CT scans would make widespread use of lung cancer screening far more feasible.
“The urgency of developing accurate, cost-effective tools for early detection of lung cancer is highlighted by the thousands of preventable lung cancer deaths each year. This data showing that the Cell-CT platform can detect lung cancer with high accuracy from sputum samples in patients at all stages of the disease, as well as identifying those who are cancer-free, is very encouraging,” said Glen J. Weiss, MD, Director of Clinical Research, Cancer Treatment Centers of America Western Regional Medical Center.
“We look forward to continuing to work with VisionGate to enlarge the study population and generate the data needed to advance development of this promising lung cancer screening test.”
